TY - JOUR
T1 - Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS
T2 - Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort
AU - Biswas, Bipasha
AU - Spitznagel, Edward
AU - Collier, Ann C.
AU - Gelman, Benjamin B.
AU - McArthur, Justin C.
AU - Morgello, Susan
AU - McCutchan, J. Allen
AU - Clifford, David B.
N1 - Funding Information:
The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) is supported by awards N01 MH22005, HHSN271201000027C, and HHSN271201000030C from the National Institutes of Health.
PY - 2014/1
Y1 - 2014/1
N2 - Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95%. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95%. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.
AB - Antiretroviral therapy (ART) has changed HIV-related illness from terminal to chronic by suppressing viral load which results in immunologic and clinical improvement. Success with ART is dependent on optimal adherence, commonly categorized as > 95%. As medication type, class and frequency of use continue to evolve, we assessed adherence levels related to viral suppression. Using a cross-sectional analysis with secondary data (n = 381) from an ongoing multi-site study on impact of ART on the Central Nervous System (CNS), we compared self-reported adherence rates with biological outcomes of HIV-RNA copies/ml, and CD4 cell/mm3. Adherence to ART measures included taking all prescribed medication as directed on schedule and following dietary restrictions. While depression was a barrier to adherence, undetectable viral suppression was achieved at pill adherence percentages lower than 95%. Practice, research and policy implications are discussed in the context of patient-, provider-, and system-level factors influencing adherence to ART.
KW - HIV/AIDS transmission and/or risk
KW - adherence
KW - depressive symptomatology
KW - immune markers
KW - treatment issues
UR - http://www.scopus.com/inward/record.url?scp=84895744998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895744998&partnerID=8YFLogxK
U2 - 10.1080/15381501.2013.859111
DO - 10.1080/15381501.2013.859111
M3 - Article
C2 - 24678283
AN - SCOPUS:84895744998
SN - 1538-1501
VL - 13
SP - 8
EP - 25
JO - Journal of HIV/AIDS and Social Services
JF - Journal of HIV/AIDS and Social Services
IS - 1
ER -